Why Has Adagio Medical Holdings (NASDAQ:ADGM) Dropped 15.62% Before the Tuesday Open?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Has Adagio Medical Holdings (NASDAQ:ADGM) Dropped 15.62% Before the Tuesday Open?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Adagio Medical Holdings (NASDAQ:ADGM) was indicated at USD 1.62 pre-market on Tuesday, November 10, 2026, 15.62% lower than a calculated prior close of USD 1.92.
A quote snapshot dated November 10 shows a trading range of USD 1.50 to USD 2.97 and an opening print of USD 2.19, which puts the high 98.0% above the low (calculated).
Volume reached about 1.10 million shares against an average of 147,310, roughly 7.5 times the norm (calculated), with a 52-week range of USD 1.50 to USD 50.70.
On October 26, 2026 the stock closed at USD 0.0967 with 22.21 million shares, a Market Value of USD 2.15 million and a trailing net loss of USD 27.14 million.

Pre-Market Decline of 15.62% for Adagio Medical Holdings

The pre-market quote of USD 1.62 sits against a calculated prior close of USD 1.92, a drop of USD 0.30 a share. The wide range of USD 1.50 to USD 2.97 with the USD 2.19 open points to unusually volatile early trading. Dividing the USD 50.70 52-week peak by the USD 1.69 October 26 high gives roughly 30 (calculated), pointing to a 1-for-30 reverse split in the price history; the ratio is inferred, not confirmed. Adagio, based in Laguna Hills, California, employs 41 people. Its ablation technology addresses atrial fibrillation as well as ventricular tachycardia, plus atrial flutter. Chief executive Todd Usen leads the firm, and its pipeline depends on continuing capital, so holders have a stake in the review and any raise.

What Could Be Behind the Move

No catalyst for the move has been confirmed in published coverage. Relevant background: on September 16, 2026 the company flagged its first treated patient in an IDE study for the vCLAS Ultra system, which targets ventricular tachycardia, and around September 23, 2026 it announced a strategic review aimed at maximising Shareholder value. Shareholders voted in October 2026 for a reverse split, with the board free to pick any ratio from 1-for-10 up to 1-for-500. Quarterly results are expected on November 11, 2026. In general terms, after a reverse split share prices often slide as holders sell the higher-priced shares, while a strategic review may lead to a takeover, combination, Capital raise or winding up. The latest full Earnings publication came out August 11, 2026, so Tuesday's move has little fresh disclosure behind it.

Valuation, Liquidity and Risk Considerations

Applying the implied split to the 22.21 million shares reported on October 26 gives about 0.74 million shares, and at USD 1.62 the market value would be roughly USD 1.2 million (calculated, unverified). The quote page reports a market value of USD 57.88 million, which does not reconcile with that and is regarded as unreliable. Three analysts had a USD 3.33 price objective on October 26, but it predates the split and cannot be compared. Early trading is light and spreads may be wide; for a micro-cap, dilution exposure is significant and reversals are possible. The figures do not indicate whether the slide or a bounce comes next, and the 1.50 low sits only 7.4% below the pre-market price (calculated).

Where Things Stand

Adagio Medical Holdings (NASDAQ:ADGM) is 15.62% lower pre-market on November 10, 2026 with no confirmed catalyst; the most plausible general explanation is post-reverse-split Volatility alongside a strategic review. At USD 1.62 the shares are not far above the 52-week floor of USD 1.50. The next data point is the Quarterly Report expected on November 11, 2026, likely showing cash and how the loss compares with the USD 27.14 million trailing total. Disclosures in a filing about financing, a Merger or the split ratio would carry more weight than early quotes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.